Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Salarius Pharmaceuticals ( (SLRX) ) has shared an update.
Salarius Pharmaceuticals has taken steps to regain compliance with Nasdaq’s equity standard by issuing and selling shares to raise its stockholders’ equity above the required $2.5 million threshold. The company is awaiting Nasdaq’s confirmation of compliance, and while its financial closing procedures for the quarter ended September 30, 2025, are incomplete, it anticipates that its upcoming quarterly report will reflect the necessary equity level.
Spark’s Take on SLRX Stock
According to Spark, TipRanks’ AI Analyst, SLRX is a Underperform.
Salarius Pharmaceuticals exhibits significant financial instability, characterized by declining revenues and persistent losses, which severely impacts its stock score. Technically, the stock is on a bearish trend, trading below major moving averages, with negative momentum indicators. The valuation is further weakened by a negative P/E ratio and absence of dividend, making it unattractive to value or income investors. Overall, the stock is highly risky and requires cautious consideration.
To see Spark’s full report on SLRX stock, click here.
More about Salarius Pharmaceuticals
Salarius Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of cancer therapies.
Average Trading Volume: 268,034
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.65M
See more insights into SLRX stock on TipRanks’ Stock Analysis page.